Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MALVERN, PA., AUG. 03, 2026 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM) (NEURONETICS OR THE COMPANY) AND JOREY CHERNETT, THE COMPANY'S SECOND LARGEST SHAREHOLDER AND MANAGING MEMBER OF POINTILLIST FAMILY OFFICE, TODAY ANNOUNCED THAT THEY HAVE CREATED A CONSTRUCTIVE FRAMEWORK FOR ALIGNMENT BETWEEN THE COMPANY'S BOARD OF DIRECTORS (THE BOARD), MANAGEMENT, AND MR. CHERNETT (THE UNDERSTANDING).

NEURONETICS AND JOREY CHERNETT ANNOUNCE SHARED VISION

MALVERN, PA., JULY 31, 2026 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A LEADER IN INTERVENTIONAL MENTAL HEALTH THAT COMBINES ITS NEUROSTAR TMS TECHNOLOGY WITH DIRECT PATIENT CARE THROUGH THE GREENBROOK NETWORK OF INTERVENTIONAL PSYCHIATRY CLINICS, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO FIVE NEW NON-EXECUTIVE EMPLOYEES AS DESCRIBED BELOW.

NEURONETICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

NEW LOCATION EXPANDS ACCESS TO ADVANCED MENTAL HEALTH TREATMENTS WHILE SERVING AS GREENBROOK'S FLAGSHIP INNOVATION CENTER AND BLUEPRINT FOR FUTURE CARE DELIVERY NEW LOCATION EXPANDS ACCESS TO ADVANCED MENTAL HEALTH TREATMENTS WHILE SERVING AS GREENBROOK'S FLAGSHIP INNOVATION CENTER AND BLUEPRINT FOR FUTURE CARE DELIVERY

GREENBROOK OPENS NATIONAL CENTER OF EXCELLENCE FOR ADVANCED INTERVENTIONAL PSYCHIATRY IN ROCKVILLE, MARYLAND

MALVERN, PA., JULY 28, 2026 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A LEADER IN INTERVENTIONAL MENTAL HEALTH THAT COMBINES ITS NEUROSTAR TMS TECHNOLOGY WITH DIRECT PATIENT CARE THROUGH THE GREENBROOK NETWORK OF INTERVENTIONAL PSYCHIATRY CLINICS, TODAY ANNOUNCED THAT IT PLANS TO RELEASE SECOND QUARTER 2026 FINANCIAL AND OPERATING RESULTS PRIOR TO MARKET OPEN ON TUESDAY, AUGUST 11, 2026. THE COMPANY WILL HOST A CONFERENCE CALL TO REVIEW ITS RESULTS AT 8:30 A.M. EASTERN TIME THE SAME DAY.

NEURONETICS TO REPORT SECOND QUARTER 2026 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL

MALVERN, PA., JULY 20, 2026 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A LEADER IN INTERVENTIONAL MENTAL HEALTH THAT COMBINES ITS NEUROSTAR TMS TECHNOLOGY WITH DIRECT PATIENT CARE THROUGH THE GREENBROOK NETWORK OF INTERVENTIONAL PSYCHIATRY CLINICS, TODAY ANNOUNCED THAT NIR NAOR WILL BE APPOINTED CHIEF FINANCIAL OFFICER EFFECTIVE JULY 23, 2026. "NIR IS A PROVEN LEADER WHO BRINGS THE FINANCIAL DISCIPLINE AND RIGOR OUR STRATEGY DEMANDS," SAID DAN REUVERS, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF NEURONETICS. "ACROSS MEDICAL DEVICE AND CARE-DELIVERY MODELS, HE HAS CONSISTENTLY DELIVERED PROFITABLE REVENUE GROWTH AND HEALTHY CASH FLOW WHILE BUILDING HIGH-PERFORMING TEAMS AND SHARPENING CAPITAL ALLOCATION. HE IS THE IDEAL PERSON TO HELP US EXECUTE OUR STRATEGY, EXPAND ACCESS TO OUR THERAPIES, AND IMPROVE THE LIVES OF THE PATIENTS WE SERVE." NAOR BRINGS MORE THAN 20 YEARS OF FINANCE AND LIFE SCIENCES EXPERIENCE. MOST RECENTLY, HE SERVED AS CHIEF FINANCIAL OFFICER OF AXOGEN (NASDAQ: AXGN), A SURGICAL SOLUTIONS LEADER IN PERIPHERAL NERVE REPAIR, WHERE HE HELPED THE COMPANY ACHIEVE PROFITABILITY AND CASH FLOW POSITIVITY WITHIN ONE YEAR, CONTRIBUTING TO THE TRIPLING OF ITS MARKET CAPITALIZATION. PREVIOUSLY, HE SERVED AS CFO OF SPECIALTY PHARMACEUTICAL COMPANY ARBOR PHARMACEUTICALS, WHERE HE LED ITS SALE TO AZURITY PHARMACEUTICALS, AND AS CFO OF THE U.S./AMERICAS BUSINESS OF GLOBAL MEDTECH COMPANY MLNLYCKE. EARLIER IN HIS CAREER, HE HELD SENIOR FINANCE LEADERSHIP ROLES AT UCB AND ASTRAZENECA ACROSS THE U.S. AND EUROPE, AFTER SERVING AS AN INVESTMENT BANKER, WORKING AS AN AUDITOR WITH KPMG, AND PRACTICING COMMERCIAL LAW. NAOR IS ALSO A CFA CHARTERHOLDER AND HAS SERVED AS BOARD MEMBER AND ADVISOR TO EMERGING LIFE SCIENCES COMPANIES. "NEURONETICS STANDS AT THE FOREFRONT OF NEUROHEALTH AND OPERATES A NATIONAL NETWORK OF CLINICS WITH SIGNIFICANT POTENTIAL", SAID NAOR. "THE OPPORTUNITY AHEAD IS MEANINGFUL, AND I AM EAGER TO WORK ALONGSIDE DAN AND THE ORGANIZATION TO STRENG

NEURONETICS APPOINTS NIR NAOR CHIEF FINANCIAL OFFICER; ANNOUNCES ADDITIONAL MANAGEMENT CHANGES

MALVERN, PA., JULY 06, 2026 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A LEADER IN INTERVENTIONAL MENTAL HEALTH THAT COMBINES ITS NEUROSTAR TMS TECHNOLOGY WITH DIRECT PATIENT CARE THROUGH THE GREENBROOK NETWORK OF INTERVENTIONAL PSYCHIATRY CLINICS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE AT THE B. RILEY SECURITIES' MIND, MUSCLE & VISION SUMMIT, AN INVITATION-ONLY INSTITUTIONAL INVESTOR EVENT BEING HELD IN-PERSON AT THE INTERCONTINENTAL BOSTON. NEURONETICS WILL PARTICIPATE IN A PANEL DISCUSSION TITLED "COMMERCIALIZING THE NEXT WAVE OF NOVEL NEUROPSYCHIATRIC DRUGS," ALONGSIDE COMPASS PATHWAYS, SCHEDULED FOR THURSDAY, JULY 16, 2026. MANAGEMENT WILL ALSO BE AVAILABLE FOR ONE-ON-ONE MEETINGS WITH INSTITUTIONAL INVESTORS THROUGHOUT THE DAY. THIS IS AN IN-PERSON, INVITATION-ONLY EVENT, AND THERE WILL BE NO LIVE WEBCAST OF THE PANEL DISCUSSION. ABOUTNEURONETICS NEURONETICS, INC. IS A LEADER IN INTERVENTIONAL MENTAL HEALTH, COMBINING INNOVATIVE TREATMENT TECHNOLOGIES WITH DIRECT PATIENT CARE. THROUGH ITS NEUROSTAR ADVANCED THERAPY SYSTEM, THE COMPANY IS A LEADING PROVIDER OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT AND, THROUGH GREENBROOK, OPERATES ONE OF THE LARGEST INTERVENTIONAL PSYCHIATRY CLINIC NETWORKS IN THE UNITED STATES, OFFERING BOTH TMS AND SPRAVATO THERAPIES. NEUROSTAR ADVANCED THERAPY IS A NON-DRUG, NONINVASIVE TREATMENT THAT CAN IMPROVE THE QUALITY OF LIFE FOR PEOPLE SUFFERING FROM NEUROHEALTH CONDITIONS WHEN TRADITIONAL MEDICATION HAS NOT HELPED. NEUROSTAR ADVANCED THERAPY IS THE LEADING TMS TREATMENT FOR MDD IN ADULTS AND IS BACKED BY WHAT WE BELIEVE IS THE LARGEST CLINICAL DATA SET OF ANY TMS TREATMENT SYSTEM FOR DEPRESSION. GREENBROOK TREATMENT CENTERS ALSO OFFER SPRAVATO (ESKETAMINE) NASAL SPRAY, A PRESCRIPTION MEDICINE INDICATED FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS AS MONOTHERAPY OR IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT. IT IS ALSO INDICATED FOR DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH AC

Neuronetics, Inc.

STIM

Price

Financial Reports

No items found.

Press Releases

Neuronetics, Inc.

STIM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

STIM